MRK
Merck & Co., Inc. NYSE Listed Jan 13, 1978$150.91
+0.94%
vs $149.50
Mkt Cap $378.3B
52w Low $77.60
93.0% of range
52w High $156.45
50d MA $138.93
200d MA $120.94
P/E (TTM)
120.7x
EV/EBITDA
29.7x
P/B
7.2x
Debt/Equity
1.0x
ROE
34.7%
P/FCF
30.6x
RSI (14)
52.60
ATR (14)
$2.97
Beta
0.28
50d MA
$138.93
200d MA
$120.94
Avg Volume
11.1M
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
126 East Lincoln Avenue · Rahway, NJ 07065 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | BMO | -0.27 | -0.13 | +51.9% | 127.77 | +0.5% | +0.2% | +0.3% | +0.0% | +0.2% | +1.8% | — |
| Apr 30, 2026 | BMO | -1.47 | -1.28 | +12.9% | 110.95 | -1.5% | -1.6% | +2.7% | +0.8% | +0.0% | +0.4% | — |
| Feb 3, 2026 | BMO | 2.01 | 2.04 | +1.5% | 113.37 | -1.5% | +2.2% | +2.1% | +1.2% | +1.8% | -3.5% | — |
| Oct 30, 2025 | BMO | 2.36 | 2.58 | +9.3% | 86.58 | -2.3% | -0.3% | -0.3% | -4.1% | +1.7% | +0.6% | — |
| Jul 29, 2025 | BMO | 2.03 | 2.13 | +4.9% | 84.06 | -5.0% | -1.7% | -1.1% | -4.4% | +1.5% | +0.7% | — |
| Apr 24, 2025 | BMO | 2.13 | 2.22 | +4.2% | 78.69 | -0.5% | +1.5% | +3.6% | +0.5% | +1.8% | +0.6% | — |
| Feb 4, 2025 | BMO | 1.85 | 1.72 | -7.0% | 99.79 | -10.8% | -9.1% | -1.2% | -1.8% | -0.9% | -1.0% | — |
| Oct 31, 2024 | BMO | 1.50 | 1.57 | +4.7% | 104.83 | -3.7% | -2.4% | -0.4% | -0.0% | -0.2% | -0.9% | — |
| Jul 30, 2024 | BMO | 2.15 | 2.28 | +6.0% | 127.78 | -3.4% | -9.8% | -1.8% | +0.6% | +1.2% | -2.5% | — |
| Apr 25, 2024 | BMO | 1.88 | 2.07 | +10.1% | 127.00 | +2.1% | +2.9% | +0.4% | -0.8% | -0.7% | -0.3% | — |
| Feb 1, 2024 | BMO | -0.09 | 0.03 | +133.3% | 120.78 | +2.4% | +4.6% | +0.0% | -0.2% | +0.6% | +0.5% | — |
| Oct 26, 2023 | BMO | 1.95 | 2.13 | +9.2% | 103.63 | -0.5% | +1.9% | -2.6% | -0.1% | +0.0% | +0.1% | — |
| Aug 1, 2023 | BMO | -2.17 | -2.06 | +5.1% | 106.65 | +2.8% | -1.3% | +0.4% | +0.0% | -0.7% | +1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 20 | Morgan Stanley | Upgrade | Equal-Weight → Overweight | $179 | $152.20 | $150.78 | -0.9% | -2.1% | +2.4% | -1.2% | +3.8% | -2.1% |
| Aug 20 | RBC Capital Mkts | Downgrade | Outperform → Sector Perform | $150 | $152.20 | $150.78 | -0.9% | -2.1% | +2.4% | -1.2% | +3.8% | -2.1% |
| Aug 12 | Daiwa Securities | Upgrade | Neutral → Outperform | $143 | $130.42 | $130.25 | -0.1% | +1.9% | +2.0% | +0.2% | +0.1% | -0.6% |
| May 6 | Citigroup | Reiterates | Neutral | $125 | $113.15 | $113.15 | +0.0% | +0.4% | -1.1% | -0.8% | -0.1% | +1.0% |
| May 1 | Wells Fargo | Maintains | Overweight → Overweight | — | $109.18 | $112.33 | +2.9% | +2.7% | +0.8% | +0.0% | +0.4% | -1.1% |
| Apr 13 | UBS | Maintains | Buy → Buy | — | $121.42 | $121.03 | -0.3% | -1.0% | -0.2% | -1.7% | -2.1% | +3.1% |
| Apr 6 | JP Morgan | Maintains | Overweight → Overweight | — | $120.87 | $120.41 | -0.4% | -0.0% | -1.3% | +3.3% | -0.4% | -1.0% |
| Mar 30 | RBC Capital | Maintains | Outperform → Outperform | — | $119.63 | $120.57 | +0.8% | -1.3% | +1.9% | +0.5% | +0.0% | -0.0% |
| Mar 20 | Citigroup | Maintains | Neutral → Neutral | — | $114.20 | $114.25 | +0.0% | -0.0% | +1.3% | +0.6% | +2.6% | -0.4% |
| Mar 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $116.21 | $115.47 | -0.6% | -0.3% | -0.3% | -0.2% | +0.4% | -1.2% |
| Feb 9 | Freedom Broker | Maintains | Hold → Hold | — | $121.93 | $121.41 | -0.4% | -3.5% | -0.4% | +1.8% | -0.0% | +1.8% |
| Feb 6 | Guggenheim | Maintains | Buy → Buy | — | $119.75 | $120.76 | +0.8% | +1.8% | -3.5% | -0.4% | +1.8% | -0.0% |
| Feb 4 | Citigroup | Maintains | Neutral → Neutral | — | $115.84 | $116.90 | +0.9% | +2.1% | +1.2% | +1.8% | -3.5% | -0.4% |
| Feb 4 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $115.84 | $116.90 | +0.9% | +2.1% | +1.2% | +1.8% | -3.5% | -0.4% |
| Feb 4 | Wells Fargo | Maintains | Overweight → Overweight | — | $115.84 | $116.90 | +0.9% | +2.1% | +1.2% | +1.8% | -3.5% | -0.4% |
| Jan 27 | Citigroup | Maintains | Neutral → Neutral | — | $107.40 | $107.50 | +0.1% | +0.5% | -0.9% | +1.3% | +1.8% | +2.8% |
| Jan 20 | TD Cowen | Maintains | Hold → Hold | — | $108.83 | $108.11 | -0.7% | +0.6% | +1.5% | -1.7% | -0.9% | -0.7% |
| Jan 8 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $108.60 | $110.61 | +1.9% | +2.2% | -0.4% | -1.2% | -0.9% | +2.5% |
| Jan 7 | UBS | Maintains | Buy → Buy | — | $108.87 | $109.51 | +0.6% | -0.2% | +2.2% | -0.4% | -1.2% | -0.9% |
| Jan 7 | Citigroup | Maintains | Neutral → Neutral | — | $108.87 | $109.51 | +0.6% | -0.2% | +2.2% | -0.4% | -1.2% | -0.9% |
| Dec 18 | BMO Capital | Upgrade | Market Perform → Outperform | — | $99.18 | $99.27 | +0.1% | +1.5% | +0.4% | +3.6% | +0.3% | +1.3% |
| Dec 15 | BofA Securities | Maintains | Buy → Buy | — | $100.30 | $99.99 | -0.3% | -0.0% | -2.0% | +0.9% | +1.5% | +0.4% |
| Dec 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $99.01 | $98.96 | -0.1% | +1.3% | -0.0% | -2.0% | +0.9% | +1.5% |
| Dec 4 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $102.27 | $102.10 | -0.2% | -1.3% | -1.2% | -0.8% | -2.1% | +0.8% |
| Dec 2 | Goldman Sachs | Maintains | Buy → Buy | — | $101.83 | $101.53 | -0.3% | -0.8% | +1.2% | -1.3% | -1.2% | -0.8% |
| Nov 24 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $97.76 | $99.12 | +1.4% | +2.7% | +5.2% | -1.0% | +0.2% | -2.9% |
| Nov 18 | Deutsche Bank | Maintains | Hold → Hold | — | $92.86 | $94.11 | +1.3% | +3.8% | -1.4% | -0.1% | +2.9% | +2.7% |
| Nov 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $85.98 | $85.77 | -0.2% | -4.1% | +1.7% | +0.6% | +1.6% | +0.6% |
| Sep 17 | Berenberg | Downgrade | Buy → Hold | — | $81.09 | $80.98 | -0.1% | +0.1% | +0.5% | -0.0% | -1.4% | -0.5% |
| Jul 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $82.63 | $82.91 | +0.3% | -1.1% | -4.4% | +1.5% | +0.7% | +1.2% |
| Jul 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $83.71 | $83.64 | -0.1% | +0.4% | -0.8% | +0.4% | -2.6% | +1.1% |
| May 14 | Citigroup | Downgrade | Buy → Neutral | — | $76.63 | $77.46 | +1.1% | -4.1% | +1.8% | +1.7% | +1.5% | +1.0% |
| Apr 17 | Guggenheim | Maintains | Buy → Buy | — | $76.46 | $76.89 | +0.6% | +2.0% | -0.2% | +1.4% | -0.4% | +1.5% |
| Feb 18 | Deutsche Bank | Downgrade | Buy → Hold | — | $83.01 | $81.13 | -2.3% | +0.3% | +2.8% | +2.4% | +2.1% | +2.0% |
| Feb 12 | Guggenheim | Maintains | Buy → Buy | — | $86.54 | $86.07 | -0.5% | -1.0% | -1.5% | -1.7% | +0.3% | +2.8% |
| Feb 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $90.74 | $90.39 | -0.4% | -1.2% | -1.8% | -0.9% | -1.0% | +0.2% |
| Feb 5 | Citigroup | Maintains | Buy → Buy | — | $90.74 | $90.39 | -0.4% | -1.2% | -1.8% | -0.9% | -1.0% | +0.2% |
| Feb 5 | BofA Securities | Maintains | Buy → Buy | — | $90.74 | $90.39 | -0.4% | -1.2% | -1.8% | -0.9% | -1.0% | +0.2% |
| Feb 5 | BMO Capital | Maintains | Market Perform → Market Perform | — | $90.74 | $90.39 | -0.4% | -1.2% | -1.8% | -0.9% | -1.0% | +0.2% |
| Jan 28 | Citigroup | Maintains | Buy → Buy | — | $97.94 | $97.35 | -0.6% | -0.5% | +0.9% | +0.7% | -0.1% | +1.0% |
| Jan 21 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $97.92 | $98.08 | +0.2% | -1.7% | -0.6% | +1.0% | -1.1% | +2.5% |
| Jan 17 | Guggenheim | Maintains | Buy → Buy | — | $100.70 | $100.47 | -0.2% | -2.8% | -1.7% | -0.6% | +1.0% | -1.1% |
| Jan 13 | Leerink Partners | Maintains | Outperform → Outperform | — | $99.25 | $99.46 | +0.2% | +1.7% | -1.3% | +0.4% | +0.6% | -2.8% |
| Jan 8 | UBS | Maintains | Buy → Buy | — | $101.02 | $100.70 | -0.3% | -1.2% | -0.6% | +1.7% | -1.3% | +0.4% |
| Jan 8 | Truist | Downgrade | Buy → Hold | — | $101.02 | $100.70 | -0.3% | -1.2% | -0.6% | +1.7% | -1.3% | +0.4% |
| Dec 20 | BMO Capital | Downgrade | Outperform → Market Perform | — | $99.52 | $98.83 | -0.7% | -1.5% | +1.3% | +0.1% | +0.4% | -0.2% |
| Nov 7 | Truist | Maintains | Buy → Buy | — | $100.73 | $101.44 | +0.7% | +0.4% | +1.7% | -2.1% | -2.1% | -0.1% |
| Nov 6 | Guggenheim | Maintains | Buy → Buy | — | $101.65 | $103.18 | +1.5% | -0.9% | +0.4% | +1.7% | -2.1% | -2.1% |
| Nov 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $102.32 | $101.78 | -0.5% | -0.4% | -0.0% | -0.2% | -0.9% | +0.4% |
| Nov 1 | BMO Capital | Maintains | Outperform → Outperform | — | $102.32 | $101.78 | -0.5% | -0.4% | -0.0% | -0.2% | -0.9% | +0.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Guindo ChirfiOff | EVP, Access, Policy & Comms | Sell | 10,000 | $135.00 | $1.4M | 36,613 | +0.21% | -1.94% |
| Aug 12, 2026 | Zachary JenniferOff | EVP, General Counsel | Sell | 80,315 | $133.46 | $10.7M | 45,509 | +0.21% | -1.94% |
| Aug 12, 2026 | DeLuca Richard R.Off | EVP&Pres, Merck Animal Heallth | Sell | 600 | $132.04 | $79K | 110,167 | +1.98% | +12.61% |
| Aug 12, 2026 | DeLuca Richard R.Off | EVP&Pres, Merck Animal Heallth | Sell | 11,099 | $131.61 | $1.5M | 110,767 | +1.98% | +12.61% |
| Aug 11, 2026 | DeLuca Richard R.Off | EVP&Pres, Merck Animal Heallth | Sell | 5,427 | $132.35 | $718K | 121,866 | +1.98% | +12.61% |
| Aug 11, 2026 | DeLuca Richard R.Off | EVP&Pres, Merck Animal Heallth | Sell | 7,410 | $131.33 | $973K | 127,293 | +1.98% | +12.61% |
| Aug 10, 2026 | DeLuca Richard R.Off | EVP&Pres, Merck Animal Heallth | Sell | 20,784 | $130.43 | $2.7M | 134,703 | +1.98% | +12.61% |
| Aug 6, 2026 | DeLuca Richard R.Off | EVP&Pres, Merck Animal Heallth | Sell | 300 | $131.02 | $39K | 155,487 | -0.38% | +0.10% |
| Aug 6, 2026 | DeLuca Richard R.Off | EVP&Pres, Merck Animal Heallth | Sell | 4,945 | $130.23 | $644K | 155,787 | -0.38% | +0.10% |
| Aug 6, 2026 | DeLuca Richard R.Off | EVP&Pres, Merck Animal Heallth | Sell | 805 | $131.02 | $105K | 160,732 | -0.38% | +0.10% |
8-K · 8.01
!! High
Perspective Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Sep 14
8-K · 2.02
!! High
Merck & Co., Inc. -- 8-K 2.02: Earnings Results
Aug 4
8-K
Merck & Co., Inc. -- 8-K Filing
May 28
SC TO-T/A
! Medium
Terns Pharmaceuticals, Inc. -- Tender Offer Amendment
Merck's tender offer to acquire Terns Pharmaceuticals at $53 per share represents a significant deal combining Merck's scale with Terns' drug development capabilities.
May 5
SC TO-T
!!! Very High
Terns Pharmaceuticals, Inc. -- Tender Offer
Merck is acquiring Terns Pharmaceuticals for $53 per share in a tender offer, gaining access to Terns' pipeline of metabolic disease treatments and expanding its pharmaceutical portfolio.
Apr 24
SC TO-T
!!! Very High
Unknown — Tender Offer
Merck's tender offer for Tern Pharmaceuticals signals acquisition intent, potentially indicating confidence in Tern's pipeline value and providing Tern shareholders with liquidity while offering Merck near-term asset diversification.
Apr 7
8-K
Merck & Co., Inc. -- 8-K Filing
Merck projects 2026 sales of $65.5-$67.0 billion and non-GAAP EPS of $5.00-$5.15, with a $3.65-per-share charge from its Cidara acquisition, signaling measured growth expectations.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 226,999,837 | $29.2B | New | Jun 2026 |
| 2 | Vanguard Capital Management Llc | 161,323,174 | $20.7B | — | Jun 2026 |
| 3 | Morgan Stanley | 89,892,042 | $9.5B | Added | Dec 2025 |
| 4 | Vanguard Portfolio Management Llc | 67,738,969 | $8.7B | Added | Jun 2026 |
| 5 | Jpmorgan Chase & Co | 52,972,983 | $6.3B | Added | Mar 2026 |
| 6 | Fmr Llc | 44,516,010 | $5.4B | Added | Mar 2026 |
| 7 | Norges Bank | 36,983,784 | $4.8B | New | Jun 2026 |
| 8 | Bank Of America Corp /de/ | 30,774,221 | $3.7B | Added | Mar 2026 |
| 9 | Northern Trust Corp | 27,090,023 | $3.3B | Reduced | Mar 2026 |
| 10 | Invesco Ltd. | 21,855,101 | $2.6B | Added | Mar 2026 |
| 11 | Bank Of New York Mellon Corp | 18,713,363 | $2.3B | Reduced | Mar 2026 |
| 12 | Franklin Resources Inc | 16,267,205 | $2.0B | Added | Mar 2026 |
| 13 | Ubs Group Ag | 13,933,630 | $1.7B | Reduced | Mar 2026 |
| 14 | State Farm Mutual Automobile Insurance Co | 13,794,969 | $1.7B | — | Mar 2026 |
| 15 | Royal Bank Of Canada | 13,201,722 | $1.6B | — | Mar 2026 |
| 16 | Wells Fargo & Company/mn | 11,446,845 | $1.4B | New | Mar 2026 |
| 17 | Nuveen, Llc | 9,662,399 | $1.2B | Reduced | Jun 2026 |
| 18 | Aqr Capital Management Llc | 8,134,262 | $1.0B | Reduced | Jun 2026 |
| 19 | Barrow Hanley Mewhinney & Strauss Llc | 7,917,866 | $952M | Added | Mar 2026 |
| 20 | Pnc Financial Services Group, Inc. | 7,286,803 | $936M | Reduced | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$378.33B
Enterprise Value
$410.52B
P/E (TTM)
120.73x
Forward P/E
29.57x
PEG Ratio
1.88x
P/B
7.19x
P/S
5.70x
P/FCF
30.61x
EV/EBITDA
29.65x
Shares Out
2.51B
Financials (TTM)
Revenue
$66.40B
Net Income
$3.17B
EBITDA
$13.84B
Free Cash Flow
$12.36B
Op Cash Flow
$16.47B
EPS Basic
$7.28
EPS Diluted
$1.25
EPS Forward
$5.10
Gross Margin
75.4%
Op Margin
16.7%
Net Margin
4.8%
Balance Sheet
Total Assets
$136.87B
Total Liab.
$84.20B
Total Equity
$52.66B
Cash
$14.56B
LT Debt
$46.75B
Book Value/Sh
$21.00
Debt/Equity
0.96x
Current Ratio
1.54
Quick Ratio
1.30
Returns & Growth
ROE
34.7%
ROA
13.3%
ROIC
20.8%
Rev Growth YoY
+1.3%
EPS Growth YoY
+7.7%
Price Returns
2W
-0.6%
1M
-2.0%
3M
+29.5%
6M
+30.9%
12M
+85.9%
Technicals
52W High
$156.45
52W Low
$77.60
50d MA
$138.93
200d MA
$120.94
RSI (14)
52.60
ATR (14)
$2.97
Beta
0.28
Avg Volume
11.1M
Dividends
Div Rate
$3.26
Div Yield
2.9%
Frequency
4
Ex-Div Date
Mar 16, 2026
Analyst Price Targets
Consensus
$128.54
High
$150.00
Low
$100.00
Median
$133.00
Data updated apr 26, 2026 1:13pm
· Source: financialmodelingprep.com